After nearly two years, charges have finally been filed in regards to the CannTrust cultivation misconduct that shocked the industry and broke patients’ hearts.
Each of the accused are facing charges of fraud, making false or misleading statements to the OCS and the market.
For those who don’t remember, in July 2019 CannTrust abruptly announced, via a newsletter, that it would stop offering medical cannabis to patients.
A whistleblower had alerted Health Canada, the agency that oversees the Cannabis Act, to misconduct at a number of the company’s cultivation sites.
The allegations are wild: Allegedly CannTrust used fake walls to hide unlicensed cannabis grows from Health Canada.
In fact, Health Canada still has yet to issue any fines, to any company or individual, under the Cannabis Act since legalization took effect in Oct.
The CannTrust case is the largest scandal in the history of Candian cannabis, shaking the confidence in the legal system for many patients and cultivators alike.
The current CannTrust leadership team is distancing itself as much as possible from its three former executives and their charges, noting that no charges have been laid against CannTrust, any of its subsidiaries or any of the company’s current directors, officers, or employees.
“Our license reinstatement is the result of an enormous amount of hard work by the CannTrust team,” said Greg Guyatt, Chief Executive Officer at CannTrust.
Since 2018, Ashley has served the cannabis industry by covering cannabis industry news, advocating for medical cannabis & the patient perspective, and creating lifestyle content that matters.